GUILLERMO GARCIA-MANERO to Anemia, Sideroblastic
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Anemia, Sideroblastic.
Connection Strength
2.323
-
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
Score: 0.760
-
MDS/MPN-RS-T justified inclusion as a unique disease entity? Best Pract Res Clin Haematol. 2020 06; 33(2):101147.
Score: 0.696
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 05; 36(5):1432-1435.
Score: 0.201
-
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia. 2022 04; 36(4):1189-1192.
Score: 0.199
-
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2022 01; 63(1):199-204.
Score: 0.194
-
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 01 09; 382(2):140-151.
Score: 0.174
-
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012 Jan 12; 119(2):569-72.
Score: 0.099